{
    "clinical_study": {
        "@rank": "161494", 
        "arm_group": [
            {
                "arm_group_label": "THS 2.2 Menthol", 
                "arm_group_type": "Experimental", 
                "description": "Ad libitum use of THS 2.2 Menthol"
            }, 
            {
                "arm_group_label": "SA", 
                "arm_group_type": "Sham Comparator", 
                "description": "Abstinence from smoking"
            }, 
            {
                "arm_group_label": "mCC", 
                "arm_group_type": "Active Comparator", 
                "description": "Ad libitum use of mCC"
            }
        ], 
        "brief_summary": {
            "textblock": "The main goal of the study is to evaluate if the ad libitum use of the THS 2.2 Menthol for 5\n      days in confinement and after 85 days of product use in an ambulatory setting, by Japanese\n      adult healthy smokers results in a reduction in the levels of biomarkers of exposure for\n      selected harmful and potentially harmful smoke constituents (HPHCs) compared to smokers\n      continuing smoking their own preferred brand of menthol conventional cigarette (mCC) and\n      smoking abstinence (SA)."
        }, 
        "brief_title": "Reduced Exposure Study Using the Tobacco Heating System 2.2 (THS 2.2) Menthol for 90 Days in Confinement and Ambulatory", 
        "completion_date": {
            "#text": "July 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Smoking", 
        "condition_browse": {
            "mesh_term": "Smoking"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Subject is Japanese.\n\n          -  Smoking, healthy subject as judged by the Investigator.\n\n          -  Subject smokes at least 10 commercially available mCCs per day (no brand\n             restrictions) for the last 4 weeks, based on self-reporting.\n\n          -  Subject has smoked for at least the last 3 consecutive years.\n\n          -  Subject does not plan to quit smoking in the next 3 months.\n\n        Exclusion Criteria:\n\n          -  As per Investigator judgment, the subject cannot participate in the study for any\n             reason (e.g., medical, psychiatric, and/or social reason).\n\n          -  The subject has received medication within 14 days or within 5 half-lives of the\n             medication (whichever is longer) which has an impact on cytochrome P450 1 A2 (CYP1A2)\n             or cytochrome P450 2 A6 (CYP2A6) activity.\n\n          -  For women: Subject is pregnant or is breast feeding.\n\n          -  For women: Subject does not agree to use an acceptable method of effective\n             contraception."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "65 Years", 
            "minimum_age": "23 Years"
        }, 
        "enrollment": {
            "#text": "160", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "October 18, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01970995", 
            "org_study_id": "ZRHM-REXA-07-JP", 
            "secondary_id": "ZRHM-REXA-07-JP"
        }, 
        "intervention": [
            {
                "arm_group_label": "THS 2.2 Menthol", 
                "description": "THS 2.2 Menthol ad libitum for 5 days in confinement prolonged by 85 days in an ambulatory setting", 
                "intervention_name": "THS 2.2 Menthol", 
                "intervention_type": "Other"
            }, 
            {
                "arm_group_label": "SA", 
                "description": "SA for 5 days in confinement prolonged by 85 days in an ambulatory setting", 
                "intervention_name": "SA", 
                "intervention_type": "Other"
            }, 
            {
                "arm_group_label": "mCC", 
                "description": "Subject's own preferred brand of mCC ad libitum for 5 days in confinement prolonged by 85 days in an ambulatory setting", 
                "intervention_name": "mCC", 
                "intervention_type": "Other"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Menthol"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Modified risk tobacco product", 
            "Conventional cigarettes", 
            "Reduced exposure", 
            "HPHCs", 
            "Ambulatory"
        ], 
        "lastchanged_date": "March 27, 2014", 
        "location": {
            "contact": {
                "last_name": "Masahiro Endo, MD"
            }, 
            "facility": {
                "address": {
                    "city": "Tokyo", 
                    "country": "Japan"
                }, 
                "name": "Osaki Hospital Tokyo Heart Center, 5-4-12, Kitashinagawa, Shinagawa-ku"
            }, 
            "investigator": {
                "last_name": "Masahiro Endo, MD", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Japan"
        }, 
        "number_of_arms": "3", 
        "official_title": "A Randomized, Controlled, Multi-center Study to Demonstrate Reductions in Exposure to Selected Smoke Constituents in Smokers Switching to THS 2.2 Menthol or Smoking Abstinence Compared to Smoking Menthol Conventional Cigarettes, for 90 Days", 
        "overall_contact": {
            "email": "prendo@tokyoheart.or.jp", 
            "last_name": "Masahiro Endo, MD", 
            "phone": "+81 3 5789 8100"
        }, 
        "overall_official": [
            {
                "affiliation": "Osaki Hospital Tokyo Heart Center", 
                "last_name": "Masahiro Endo, MD", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "Philip Morris Products S.A.", 
                "last_name": "Christelle Haziza, PhD", 
                "role": "Study Chair"
            }
        ], 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Japan: Institutional Review Board", 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "June 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "description": "To demonstrate the reduction of exposure to respectively 1,3-butadiene; acrolein; benzene and carbon monoxide (HPHCs) after 5 days of switching from  mCC to THS 2.2 Menthol as compared to mCC.", 
                "measure": "To demonstrate the levels of monohydroxybutenyl mercapturic acid (MHBMA); 3-hydroxypropylmercapturic acid (3-HPMA); S-phenylmercapturic acid (S-PMA) expressed as concentration adjusted to creatinine in 24-hour urine and carboxyhemoglobin (COHb) in blood.", 
                "safety_issue": "No", 
                "time_frame": "5 days"
            }, 
            {
                "description": "To demonstrate the reduction of exposure to 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone after 90 days of switching from mCC to THS 2.2 Menthol as compared to mCC.", 
                "measure": "To demonstrate the levels of Total 4-(methylnitrosamino)-1-(3- pyridyl)-1-butanol) (Total NNAL)", 
                "safety_issue": "No", 
                "time_frame": "90 days"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01970995"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "Philip Morris Products S.A.", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Philip Morris Products S.A.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "August 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Open Label", 
        "study_type": "Interventional", 
        "verification_date": "March 2014"
    }
}